RMTI ROCKWELL MEDICAL, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1041024 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-4.0%
TTM net income YoY-2.5%
TTM EPS YoY95.2%
Revenue 3-yr CAGR-3.5%
Net income 3-yr CAGR—
Margins
Gross margin18.1%
Operating margin-7.1%
Net margin-7.8%
FCF margin1.1%
EBITDA margin-4.6%
Returns
ROE-16.1%
ROA-9.9%
ROIC (approx.)-12.8%
Asset turnover1.27x
Leverage & solvency
Liabilities / assets42.0%
Debt / equity0.27x
Current ratio2.47x
Interest coverage-4.56x
Cash quality & payout
Operating cash flow / net income-0.47x
Accruals ratio-14.5%
Payout ratio—
Capex / revenue2.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $19.12M | $17.78M | $17.34M | $18.35M | $15.93M | $16.07M | $18.91M | $24.66M |
| Cost of revenue | $16.01M | $14.54M | $14.44M | $14.47M | $13.65M | $13.57M | $15.87M | $21.03M |
| Gross profit | $3.11M | $3.24M | $2.90M | $3.88M | $2.27M | $2.50M | $3.04M | $3.63M |
| R&D expense | $114,000 | $40,000 | — | $0 | $0 | $0 | $0 | $1,000 |
| SG&A expense | $3.80M | $3.69M | $3.81M | $3.74M | $3.33M | $3.28M | $3.69M | $3.31M |
| Operating income | -$2.22M | -$1.06M | -$1.48M | -$398,000 | -$1.58M | -$1.35M | -$1.36M | -$519,000 |
| Interest expense | $282,000 | $281,000 | $282,000 | $286,000 | $285,000 | $276,000 | $277,000 | $289,000 |
| Net income | -$2.32M | -$1.17M | -$1.60M | -$554,000 | -$1.75M | -$1.49M | -$1.51M | -$756,000 |
| EBITDA | -$1.82M | -$661,000 | -$969,000 | $148,000 | -$1.18M | -$949,000 | -$821,000 | $24,000 |
| EPS (basic) | -0.59 | -0.34 | -0.04 | — | -0.49 | -0.48 | -0.04 | — |
| EPS (diluted) | — | — | -0.04 | — | -0.05 | -0.05 | -0.04 | — |
| Weighted avg. shares (diluted) | 3.97M | 3.96M | 39.42M | — | 3.60M | 3.43M | 34.11M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $10.63M | $10.52M | $9.61M | $10.71M | $13.61M | $12.48M | $11.39M | $15.66M |
| Short-term investments | — | — | — | $14.29M | — | — | — | $5.94M |
| Receivables | $9.80M | $8.30M | $8.82M | $8.14M | $8.33M | $8.08M | $9.67M | $8.29M |
| Inventory | $2.94M | $2.82M | $3.06M | $3.42M | $3.96M | $4.16M | $5.04M | $5.78M |
| Current assets | $37.17M | $36.36M | $36.94M | $38.16M | $37.51M | $31.61M | $33.03M | $37.03M |
| PP&E, net | $4.91M | $4.62M | $4.33M | $4.63M | $4.95M | $5.13M | $5.39M | $5.79M |
| Goodwill | $921,000 | $920,000 | $921,000 | $921,000 | $921,000 | $921,000 | $921,000 | $921,000 |
| Intangibles | $9.24M | $9.38M | $9.52M | $9.66M | $9.79M | $9.93M | $10.07M | $10.21M |
| Total assets | $57.08M | $56.53M | $57.42M | $57.15M | $57.49M | $52.62M | $53.96M | $59.21M |
| Current liabilities | $15.07M | $11.17M | $9.87M | $9.58M | $9.58M | $10.95M | $11.21M | $14.09M |
| Short-term debt | $2.83M | $1.77M | $707,000 | $0 | — | — | — | — |
| Long-term debt | $6.22M | $7.24M | $8.21M | $8.83M | $8.74M | $8.65M | $8.56M | $8.47M |
| Total debt | $9.05M | $9.00M | $8.91M | $8.83M | $8.74M | $8.65M | $8.56M | $8.47M |
| Total liabilities | $23.95M | $21.44M | $21.57M | $20.16M | $20.47M | $22.22M | $22.44M | $26.62M |
| Shareholders' equity | $33.13M | $35.09M | $35.86M | $36.98M | $37.02M | $30.41M | $31.52M | $32.59M |
| Net debt | -$1.58M | -$1.52M | -$695,000 | -$1.89M | -$4.87M | -$3.83M | -$2.83M | -$7.19M |
| Shares outstanding | 3.97M | 39.72M | 39.47M | 3.94M | 3.94M | 3.44M | 34.26M | 34.06M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.53M | $2.08M | -$167,000 | $2.29M | -$1.31M | $1.84M | -$3.49M | $865,000 |
| Capital expenditure | $722,000 | $617,000 | $425,000 | $86,000 | $229,000 | $164,000 | $63,000 | $395,000 |
| Free cash flow | -$2.25M | $1.46M | -$592,000 | $2.21M | -$1.54M | $1.68M | -$3.55M | $470,000 |
| Investing cash flow | $1.76M | -$487,000 | -$122,000 | -$4.13M | -$4.31M | -$103,000 | -$1,000 | -$332,000 |
| Financing cash flow | -$118,000 | -$683,000 | -$813,000 | -$1.06M | $6.74M | -$650,000 | -$783,000 | $2.79M |
| Depreciation & amortization | $400,000 | $400,000 | $511,000 | $546,000 | $400,000 | $400,000 | $539,000 | $543,000 |
| Stock-based compensation | $391,000 | $403,000 | $479,000 | $457,000 | $532,000 | $382,000 | $445,000 | $382,000 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.